This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Healthcare (THC) Drops Plans to Spin Off Conifer Segment
by Zacks Equity Research
Tenet Healthcare (THC) aborts its Conifer spin-off plan based on its solid business opportunities and strong pipeline prospects. It also reaffirmed its 2022 guidance.
How Much Upside is Left in Addus HomeCare (ADUS)? Wall Street Analysts Think 62%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 61.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Addus HomeCare (ADUS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADUS or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of -2.15% and -5.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.12% and -0.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Addus HomeCare (ADUS) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 4.23% and -1.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Addus HomeCare (ADUS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
Biden Chips in $400B for Home Healthcare: Stocks to Watch
by Sapna Bagaria
Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.
Is a Surprise Coming for Addus HomeCare (ADUS) This Earnings Season?
by Zacks Equity Research
Addus HomeCare (ADUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Encompass Health (EHC) Gain From Inpatient Rehab Business?
by Zacks Equity Research
Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
CVS Health's (CVS) Front Store Sales Robust, LTC Suffers
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Addus HomeCare's (ADUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Addus HomeCare (ADUS).
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, Fulgent Genetics and Hologic
3 MedTech Growth Stocks With Solid Prospects for 2021
by Zacks Equity Research
Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.
Bet on These 5 Low Leverage Stocks to Avoid Portfolio Losses
by Aparajita Dutta
Debt financing is desirable as long as the companies succeed in generating a higher rate of return compared to the interest rate. You may consider adding TITN, SAIA, BCC, ODP, ADUS in your portfolio
Is Addus HomeCare (ADUS) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Addus HomeCare (ADUS).
Quest Diagnostics (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ADUS vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?